Lymphocyte interactions with extracellular matrix proteins and endothelium in renal allograft recipients.
Recent data indicate that extracellular matrix (ECM) proteins can provide costimulatory signals during the process of T cell activation. Those proteins accumulate in situ during allograft rejection; therefore, it may be expected that local ECM: T cell interactions may be relevant in the immunopathology of rejection. T cell adhesion from allograft of recipients with stable renal function (RAR-S) and patients with biopsy-proven chronic rejection (RAR-CH) to ECM proteins (collagen type IV, fibronectin, elastin) was measured. Furthermore, T cell: endothelial interactions in vitro were studied. Adhesion of PHA-activated T cells from both groups of allograft recipients to fibronectin, collagen type IV and elastin was significantly lower than in healthy blood donors. Moreover, similar pattern of activity was observed when T cell attachment to resting and activated endothelium was studied. There were no significant differences in the number of circulating CD45RO and CD4 positive T cells. We observed a higher (although not significantly) adhesion of the T cells to resting human dermal microvascular endothelial cells (HMEC) in the chronic stages of rejection, which can suggest that the immunosuppressive protocol used in the treatment of chronic rejection is insufficient to control immunopathologic phenomena occurring in that process. Therefore, it may be argued that too low immunosuppression can be one of the factors responsible for the development of this complication.
Nowaczyk
M
M
Department of Clinical Immunology, University Medical School, Warsaw, Poland.
Górski
A
A
Korczak-Kowalska
G
G
Wierzbicki
P
P
Wyzgał
J
J
Durlik
M
M
Orłowska
A
A
D002448:Cell Adhesion; D002908:Chronic Disease; D003094:Collagen / Q000276:immunology; D004549:Elastin / Q000276:immunology; D004730:Endothelium, Vascular / Q000276:immunology*; D016326:Extracellular Matrix Proteins / Q000276:immunology*; D005260:Female; D005353:Fibronectins / Q000276:immunology; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous
D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D007166:Immunosuppressive Agents; D003094:Collagen; D004549:Elastin